{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:23:16Z","timestamp":1782487396875,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.carrev.2018.05.018","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T18:11:59Z","timestamp":1528222319000},"page":"215-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"20","author":[{"given":"Poonam","family":"Velagapudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Turagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Kolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Hyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert D.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Leopold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Dawn","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2018.05.018_bb0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/euhj.2001.2706","article-title":"The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina","volume":"23","author":"Mannheimer","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.05.018_bb0010","first-page":"e38","article-title":"Heart disease and stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.018_bb0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijcard.2009.09.538","article-title":"Fatality, morbidity and quality of life in patients with refractory angina pectoris","volume":"147","author":"Andrell","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2018.05.018_bb0020","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCULATIONAHA.106.671545","volume":"116","author":"Erbs","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.018_bb0025","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCRESAHA.109.200386","article-title":"Human studies of angiogenic gene therapy","volume":"105","author":"Gupta","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.018_bb0030","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.CIR.0000057526.10455.BD","article-title":"Adult stem cell therapy in perspective","volume":"107","author":"Perin","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.018_bb0035","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/CIRCRESAHA.111.245993","article-title":"Intramyocardial, autologous CD34+ cell therapy for refractory angina","volume":"109","author":"Losordo","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.018_bb0040","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1161\/CIRCULATIONAHA.106.687376","article-title":"Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I\/IIa double-blind, randomized controlled trial","volume":"115","author":"Losordo","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.018_bb0045","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3727\/096368916X691484","article-title":"Autologous CD34+ cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study","volume":"25","author":"Henry","year":"2016","journal-title":"Cell Transplant"},{"key":"10.1016\/j.carrev.2018.05.018_bb0050","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jcin.2016.05.003","article-title":"The RENEW trial: efficacy and safety of intramyocardial autologous CD34(+) cell administration in patients with refractory angina","volume":"9","author":"Povsic","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.05.018_bb0055","first-page":"908","article-title":"Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials","volume":"29","author":"Li","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.carrev.2018.05.018_bb0060","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/CIRCRESAHA.115.308056","article-title":"Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: a systematic review and meta-analysis","volume":"118","author":"Khan","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2018.05.018_bb0065","series-title":"European heart journal","article-title":"Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials","author":"Henry","year":"2018"},{"key":"10.1016\/j.carrev.2018.05.018_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.carrev.2018.05.018_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.carrev.2018.05.018_bb0080","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/CIRCULATIONAHA.105.541268","article-title":"Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction","volume":"113","author":"Iwasaki","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.05.018_bb0085","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1161\/01.CIR.0000128596.49339.05","article-title":"Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies","volume":"109","author":"Losordo","year":"2004","journal-title":"Circulation"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918302409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918302409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:15:25Z","timestamp":1761560125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838918302409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1553838918302409"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2018.05.018","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2018.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}